Clinical Trial

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 21, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-22; most recent amendment 2024-10-17.
Status change: Not Yet Recruiting → Recruiting 2024-10-17
Trial Details
NCT Number NCT06522828
Lead Sponsor Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
Enrollment 80 participants
Start Date 2024-10-10
Primary Completion 2025-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2024-10-21